# Carrilizumab Combined With White Purple for Squamous Cell Carcinoma of Skin

> **NCT05886140** · NA · UNKNOWN · sponsor: **Henan Cancer Hospital** · enrollment: 24 (estimated)

## Conditions studied

- Squamous Cell Carcinoma of the Skin

## Interventions

- **DRUG:** Carrilizumab with albumin-binding paclitaxel

## Key facts

- **NCT ID:** NCT05886140
- **Lead sponsor:** Henan Cancer Hospital
- **Sponsor class:** OTHER_GOV
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-06-08
- **Primary completion:** 2025-04-30
- **Final completion:** 2025-04-30
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2023-08-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05886140

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05886140, "Carrilizumab Combined With White Purple for Squamous Cell Carcinoma of Skin". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT05886140. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*